For biotech dealmakers, it’s everything, everywhere all at once

[cafead]

via Biotech executives are reaching into a deep bag of tricks to come up with the best possible ways to live up to their ultimate potential. The dual-track option, where a company pursues both an IPO and an acquisition, is becoming not just the norm, but a necessity.

article source